2.81
Alnylam Pharmaceuticals, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
billions USD
FY21:
FY22:
2.69
FY23:
2.98
FY24:
3.30
FY25:
4.05
(positive)
Change from FY21 to FY25
billions USD
FY21:
0.83
FY22:
0.85
FY23:
0.85
FY24:
0.94
FY25:
0.92
Total assets
Change from FY21 to FY25
billions USD
FY21:
3.64
FY22:
3.55
FY23:
3.83
FY24:
4.24
FY25:
4.97
Liabilities & Equity
(negative)
Change from FY21 to FY25
billions USD
FY21:
0.70
FY22:
0.77
FY23:
0.97
FY24:
1.19
FY25:
1.47
(negative)
Change from FY21 to FY25
billions USD
FY21:
2.36
FY22:
2.94
FY23:
3.08
FY24:
2.99
FY25:
2.71
(positive)
Change from FY21 to FY25
billions USD
FY21:
0.59
FY22:
−0.16
FY23:
−0.22
FY24:
0.07
FY25:
0.79
Total liabilities & equity
Change from FY21 to FY25
billions USD
FY21:
3.64
FY22:
3.55
FY23:
3.83
FY24:
4.24
FY25:
4.97
All amounts in billions USD